An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Trial Profile

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 May 2017

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019.
    • 16 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.
    • 08 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top